Local Injections of Fluorouracil for Eyelid Hordeolum Authors: Mengzhe Qin, Yutong Liang, Xueshang Su, Jun Zhuang, Ziming Zhang, Hongli Chai, Jintian Hu Published: 2026 ABSTRACT Summary:Hordeolum is usually self-limited, but a subset of patients develop persistent, symptomatic induration or prefer to avoid incision and curettage in the cosmetically sensitive eyelid. Currently, treatment methods for hordeolum mainly include local warm compresses, local or systemic antibiotic therapy, and abscess incision and drainage. We describe a small case series of 4 female patients with eyelid inflammatory nodules within the hordeolum–chalazion spectrum treated with local injection of 6-fold diluted 5-fluorouracil. Clinical response and adverse events were recorded. Two patients achieved complete clinical resolution within 3 to 7 days after a single injection. One bilateral case improved rapidly after the initial injection; the right-sided lesion resolved by day 7, whereas a left-sided induration persisted despite a second injection and remained essentially unchanged at follow-up. One long-standing post–incision-and-drainage case showed marked reduction by day 2 and further improvement by day 7 but did not completely resolve. No treatment-related adverse events were observed, and no recurrence was noted in cases with complete resolution during follow-up. Local injection of 6-fold diluted 5-fluorouracil may represent a potential minimally invasive option for selected patients with persistent eyelid inflammatory nodules. Responses were variable in this small uncontrolled series; further controlled studies are warranted to clarify efficacy, optimal dosing, and safety. Hordeolum is a common eyelid infection that usually responds to conservative measures such as warm compresses and topical antibiotics, whereas a subset of patients develop persistent, symptomatic induration or prefer to avoid incision and drainage.1,2 The drug 5-fluorouracil (5-FU) is a well-established antimetabolite with antifibrotic effects in ophthalmology and has been used periocularly to modulate wound healing and scarring. Here, we report a small case series using local injection of 6-fold diluted 5-FU for persistent eyelid inflammatory nodules, and describe clinical outcomes and safety.3 CASES REPORT Case 1 A 29-year-old woman presented with a 3-day history of erythema, swelling, and pain of the left upper eyelid, as shown in Figure 1. Pretreatment ultrasonography showed decreased echogenicity in the dermal and fatty layers. She received a local injection of 0.3 mL of 6-fold diluted 5-FU. Swelling began to regress on day 1 after injection and was markedly reduced on day 2; the swelling resolved by day 4, with complete clinical recovery by day 7. Follow-up ultrasonography on day 4 demonstrated a small hypoechoic area (0.55 × 0.24 cm) with minimal Doppler flow. No adverse events or recurrence were noted at the latest follow-up. The patient is a 29-year-old woman, presenting with swelling and pain in the left upper eyelid. A, The patient’s upper eyelid is markedly red and swollen with pain. B, The swelling of the eyelids is significantly reduced 2 days after injection. Case 2 A 42-year-old woman developed a hordeolum of the right lower eyelid 2 weeks before presentation; pain improved spontaneously but a persistent indurated nodule remained. She received 0.3 mL of 6-fold diluted 5-FU, with marked improvement by day 1 after injection and complete resolution by day 3. No adverse events or recurrence were noted at the latest follow-up. Case 3 A 27-year-old woman developed hordeola of both upper eyelids 20 days before presentation, as shown in Figure 2. Each eyelid received 0.3 mL of 6-fold diluted 5-FU for treatment. Bilateral swelling improved by day 1 after injection; the right lesion resolved by day 7, whereas the left lesion persisted as a palpable induration. An additional 0.2 mL of 6-fold diluted 5-FU injection was administered after the first treatment, leading to partial reduction but not complete resolution. The left-sided induration remained essentially unchanged at the latest follow-up. The patient is a 27-year-old woman, presenting with swelling and pain both upper eyelids. A, Both of the patient’s upper eyelids are markedly red and swollen with pain. B, The swelling and pain of the right eyelids is significantly reduced 7 days after injection, whereas the left lesion persisted as a palpable induration. Case 4 A 43-year-old woman had a persistent hordeolum of the right upper eyelid for about 1 year despite topical Tobradex, oral levofloxacin, and prior incision and drainage (date unavailable). She received 0.3 mL of 6-fold diluted 5-FU. The lesion decreased substantially by day 2 after injection; by day 7, it had further reduced in size but had not completely resolved. All patients were treated with a prepared injection solution composed of fluorouracil, lidocaine, and normal saline mixed at a 1:1:4 ratio, administered as a local injection into the lesion using a 34-gauge needle. DISCUSSION From a plastic and reconstructive perspective, management of eyelid inflammation and nodularity is clinically relevant because periocular soft-tissue interventions (including injections and eyelid surgery) are common and even minor lesions can have disproportionate functional and aesthetic impact.4,5 Although many hordeola resolve spontaneously, a subset of patients develop persistent, symptomatic induration or prefer to avoid incision and curettage in this cosmetically sensitive region. In this setting, a minimally invasive, repeatable injectable approach may be of practical value, particularly when surgical drainage is undesirable. Moreover, periocular 5-FU has precedent in modulating scarring and may represent a nonsteroidal alternative in selected patients in whom corticosteroid-related risks are a concern.6 In this small case series, local injection of 6-fold diluted 5-FU was followed by rapid reduction in swelling in several patients, with complete clinical resolution in 2 cases and incomplete or persistent induration in 2 cases. We selected 5-FU because it is a well-established antimetabolite in ophthalmology with antifibrotic properties. Periocular/subconjunctival 5-FU has been used to modulate wound healing and limit fibroblast-driven scarring, and intralesional 5-FU has also been reported in oculofacial scar management; exploratory work has examined local 5-FU injection for chalazion-like lesions.7,8 These precedents support the feasibility of periocular administration and provide a biologically plausible rationale for carefully monitored off-label use in selected patients. Clinically, eyelid inflammatory lesions may evolve from acute inflammation to a more chronic, indurated stage in which tissue remodeling contributes to persistence. Because 5-FU can inhibit proliferating fibroblasts and reduce extracellular matrix deposition, we hypothesized that local 5-FU might facilitate resolution of persistent induration by attenuating remodeling processes after the acute phase subsides.9,10 In this study, patients were treated in the setting of persistent symptoms or patient preference to avoid incision and curettage, rather than routine early self-limited presentations. Nevertheless, given the self-limited nature of many hordeola and the absence of a control group, our findings should be interpreted as preliminary and hypothesis-generating. Larger controlled studies are needed to define comparative effectiveness versus conservative measures or steroid injection and to identify the patient subset most likely to benefit. CONCLUSIONS The use of fluorouracil injections represents a novel approach to treating hordeolum. However, there are scant descriptions of this treatment in the literature, and the specific mechanism by which fluorouracil acts in the treatment of hordeolum remains unclear, necessitating further research. Clinicians should also monitor the efficacy and safety of fluorouracil when employing it to treat styes. DISCLOSURES The authors have no financial interest to declare in relation to the content of this article. PATIENT CONSENT The patients provided written consent for the use of their images. ETHICAL APPROVAL According to institutional policy, this retrospective case series using de-identified data was exempt from full ethics review. Written informed consent for publication of clinical information and images was obtained from all patients.